Towns in Parker and Wise counties are recovering from a severe storm that swept in tornadoes, caused deaths and extensive ...
Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...
Sabastian Sawe made history at the TCS London Marathon by becoming the first man to officially break two hours for the ...
WASHINGTON — The U.S. Space Force has awarded agreements worth up to $3.2 billion to a group of 12 companies to develop ...
Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical ...
A 13-year-old boy with no history presented after 4 days of progressively worsening whole body rash.Nine days before ...
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – ...
12d
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results